Molly C. Carr

4.1k total citations · 1 hit paper
33 papers, 3.1k citations indexed

About

Molly C. Carr is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Molly C. Carr has authored 33 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Molecular Biology and 7 papers in Surgery. Recurrent topics in Molly C. Carr's work include Diabetes Treatment and Management (16 papers), Diabetes Management and Research (16 papers) and Metabolism, Diabetes, and Cancer (9 papers). Molly C. Carr is often cited by papers focused on Diabetes Treatment and Management (16 papers), Diabetes Management and Research (16 papers) and Metabolism, Diabetes, and Cancer (9 papers). Molly C. Carr collaborates with scholars based in United States, United Kingdom and Japan. Molly C. Carr's co-authors include John D. Brunzell, Samir S. Deeb, Susan J. Murdoch, John D. Brunzell, Amir F. Ayyobi, Nancy Fúgate Woods, John E. Hokanson, Murray Stewart, Michael E. Mendelsohn and Judith L. Turgeon and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

Molly C. Carr

33 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Emergence of the Metabolic Syndrome with Menopause

2003 1.1k citations Molly C. Carr The Journal of Clinical Endocrinology & Metabolism profile →

Peers

Molly C. Carr

EDM

PHYSI

EPIDE

SURGE

GENET

Glenn M. Ward Australia

Marcos Antônio Tambascia Brazil

Sridhar Nambi United States

Cosimo Giannini Italy

M. Loredana Marcovecchio Italy

Mary Ann Banerji United States

Y. Antero Kesäniemi Finland

Dee Pei Taiwan

Kaj Lahti Finland

S. John Weisnagel Canada

Glenn M. Ward Australia

Molly C. Carr

2.1k ×1.1

EDM

701 ×1.1

PHYSI

666 ×1.1

EPIDE

1.0k ×1.8

SURGE

645 ×1.3

GENET

Citations per year, relative to Molly C. Carr Molly C. Carr (= 1×) peers Glenn M. Ward

Countries citing papers authored by Molly C. Carr

Since Specialization

Citations

This map shows the geographic impact of Molly C. Carr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Molly C. Carr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Molly C. Carr more than expected).

Fields of papers citing papers by Molly C. Carr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Molly C. Carr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Molly C. Carr. The network helps show where Molly C. Carr may publish in the future.

Co-authorship network of co-authors of Molly C. Carr

This figure shows the co-authorship network connecting the top 25 collaborators of Molly C. Carr. A scholar is included among the top collaborators of Molly C. Carr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Molly C. Carr. Molly C. Carr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blevins, Thomas, Dominik Dahl, Federico Pérez Manghi, et al.. (2025). Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. The Lancet. 405(10497). 2290–2301. 4 indexed citations

Bergenstal, Richard M., Athena Philis‐Tsimikas, Carol Wysham, et al.. (2024). Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes Obesity and Metabolism. 26(8). 3020–3030. 11 indexed citations

Bergenstal, Richard M., Ruth S. Weinstock, Chantal Mathieu, et al.. (2024). Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. The Lancet. 404(10458). 1132–1142. 19 indexed citations

Wysham, Carol, Harpreet S. Bajaj, Stefano Del Prato, et al.. (2024). Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. New England Journal of Medicine. 391(23). 2201–2211. 21 indexed citations

Rosenstock, Julio, Antonio Nino, Joseph Soffer, et al.. (2020). Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care. 43(10). 2509–2518. 45 indexed citations

Åhrén, Bo, Molly C. Carr, Karen Murphy, et al.. (2017). Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice. 126. 230–239. 20 indexed citations

Home, Philip, Bo Åhrén, Jane E.B. Reusch, et al.. (2017). Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice. 131. 49–60. 33 indexed citations

Matthews, Jessica, Rickey R. Reinhardt, & Molly C. Carr. (2016). Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes. Postgraduate Medicine. 128(4). 391–397. 3 indexed citations

Wilson, Timothy H., et al.. (2016). Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs. Current Medical Research and Opinion. 33(3). 431–438. 6 indexed citations

10.

Weissman, Peter N., Molly C. Carr, June Ye, et al.. (2014). HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 57(12). 2475–2484. 115 indexed citations

11.

Hompesch, Marcus, Angela R. Jones-Leone, Molly C. Carr, et al.. (2014). Albiglutide does not impair the counter‐regulatory hormone response to hypoglycaemia: a randomized, double‐blind, placebo‐controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 17(1). 82–90. 26 indexed citations

12.

Leiter, Lawrence A., Molly C. Carr, Murray Stewart, et al.. (2013). 1.4 Harmony 8: Once Weekly (QW) GLP1 Agonist Albiglutide (Albi) vs. Sitagliptin (Sita) in Type 2 Diabetes (T2D) Pts With Renal Impairment (RI): Week 26 Results (68-OR). 11(3). 76–77. 6 indexed citations

13.

Woods, Nancy Fúgate, et al.. (2006). Increased urinary cortisol levels during the menopause transition. Menopause The Journal of The North American Menopause Society. 13(2). 212–221. 76 indexed citations

14.

Carr, Molly C., John D. Brunzell, & Samir S. Deeb. (2004). Ethnic differences in hepatic lipase and HDL in Japanese, black, and white Americans. Journal of Lipid Research. 45(3). 466–473. 29 indexed citations

15.

Carr, Molly C.. (2003). The Emergence of the Metabolic Syndrome with Menopause. The Journal of Clinical Endocrinology & Metabolism. 88(6). 2404–2411. 1102 indexed citations breakdown →

16.

Deeb, Samir S., Alberto Zambon, Molly C. Carr, Amir F. Ayyobi, & John D. Brunzell. (2003). Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. Journal of Lipid Research. 44(7). 1279–1286. 152 indexed citations

17.

Meyers, Charles D., Molly C. Carr, Sang Gyu Park, & John D. Brunzell. (2003). Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia. Annals of Internal Medicine. 139(12). 996–1002. 54 indexed citations

18.

Murdoch, Susan J., Gertrud Wolfbauer, Hal Kennedy, et al.. (2002). Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. Journal of Lipid Research. 43(2). 281–289. 32 indexed citations

19.

Carr, Molly C., John E. Hokanson, Samir S. Deeb, et al.. (2001). The Contribution of Intraabdominal Fat to Gender Differences in Hepatic Lipase Activity and Low/High Density Lipoprotein Heterogeneity1. The Journal of Clinical Endocrinology & Metabolism. 86(6). 2831–2837. 99 indexed citations

20.

Carr, Molly C., Alberto Zambon, Ellen Siobhan Mitchell, et al.. (2000). Changes in LDL Density across the Menopausal Transition. Journal of Investigative Medicine. 48(4). 245–250. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact